True Fighter for India

Date: 06/07/2013

Publication:

India Abroad

Aziz Haniffa profiles Amita Gupta, who is revolutionizing the understanding and treatment of a plethora of deadly diseases.

An exerpt…

Despite gargantuan challenges, why is she virtually obsessed with trying to make a difference in India? “India is where my family is from and where I have felt most connected to the people — to the public health needs,” she replied. “India is such a complex and dynamic place where almost every infectious disease in the textbooks exists, so there is so much to learn and so much to be done. It also is a place where there are smart people and opportunities to build infrastructure to study these infectious diseases. There is a clear, compelling public health need. And if solutions can be sought for India that are scalable and cost-effective there, they have great relevance to the rest of the world.”

Read the full article

Clinical Trials

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More